



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/889,094	10/19/2001	Andreas Bergmann	2582,022	7928
7590		05/16/2008		
Kathy Smith Dias, Esq. HESLIN ROTHEMBERG FARLEY & MESITI P.C. 5 Columbia Circle Albany, NY 12203-5160			EXAMINER	
			PAK, MICHAEL D	
			ART UNIT	PAPER NUMBER
			16-46	
			MAIL DATE	DELIVERY MODE
			05/16/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 09/889,094	Applicant(s) BERGMANN ET AL.
	Examiner Michael Pak	Art Unit 1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(o).

Status

- 1) Responsive to communication(s) filed on 20 March 2008.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 7-13 is/are pending in the application.
- 4a) Of the above claim(s) 11-13 is/are withdrawn from consideration.
- 5) Claim(s) 9 is/are allowed.
- 6) Claim(s) 7,8 and 10 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No.(s)/Mail Date 3-20-08
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____
 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 20, 2008 has been entered.

Response to Amendment

2. Applicant's arguments filed March 20, 2008, have been fully considered but they are not found persuasive.
3. Claims 1-6 have been cancelled. Claims 11-13 are withdrawn. Claims 7-10 are examined below.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

4. Claims 7 and 10 are rejected under 35 U.S.C. 102(e) as being anticipated by Rapoport et al. (US 6,747,139).

Rapoport et al. disclose monoclonal antibodies against hTSH receptor which block TSH and autoantibodies (columns 15-19). The hTSH receptor comprises the FDSH sequences (sequence listings).

Applicants argue that there is no evidence that Rapoport ever made antibodies to any hTSH epitope nor monoclonal antibodies which specifically bind to the FDSH sequence of TSH receptor. However, column 15-19 clearly recite monoclonal antibodies against hTSH receptor which block TSH and autoantibodies. The antibody of Rapoport has the function of binding hTSH and block hTSH receptor binding TSH or autoantibodies thus the antibody must be directed to an epitope of hTSH. The antibody is directed against hTSH which comprises the FDSH sequence of the TSH receptor. Thus the antibody inherently has the ability to bind FDSH and sequence comprising FDSH.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 7-8 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rapoport et al. (US 6,747,139) as applied to claim 7-8 above, and further in view of Vandenbark (US 5,614,192).

Teachings of Rapoport et al. is discussed above. Rapoport et al. does not teach humanized antibodies.

Vandenbark disclose and teach humanized antibodies (columns 23-24).

It would have been obvious to one of ordinary skill in the art at the time of the invention to use the monoclonal antibodies of Rapoport et al. to humanize the antibody using the teachings of Vandembark. One of ordinary skill in the art would have been motivated to make the humanized antibody because Rapoport et al. teach the importance of antibodies for treatment of Graves' disease and the humanized antibodies would provide the optimal product for such treatment. The humanizing of antibodies is an art well known to one of ordinary skill in the art and expectation of success is extremely high.

Applicants argue that teachings of Vandemark do not compensate for the deficiencies in the teachings of Rapoport with respect to the significance of the FDSH sequence of the hTSH receptor as discussed above. However, as discussed above, column 15-19 clearly recite monoclonal antibodies against hTSH receptor which block TSH and autoantibodies. The antibody of Rapoport has the function of binding hTSH and block hTSH receptor binding TSH or autoantibodies thus the antibody must be directed to an epitope of hTSH. The antibody is directed against hTSH which comprises the FDSH sequence of the TSH receptor. Thus the antibody inherently has the ability to bind FDSH.

Claim 9 is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak whose telephone number is 571-272-0879. The examiner can normally be reached on 8:00 - 2:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael Pak/
Primary Examiner, Art Unit 1646
7 May 2008